Business
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
BOSTON, December 11, 2025--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1066,"height":220,"url":"https://media.zenfs.com/en/business-wire.com/d07cbeb121c68ed5e1d34236cca98ce5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_meeMptsLM0kGdpQ5TkNWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d07cbeb121c68ed5e1d34236cca98ce5","width":960,"height":198},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3Fuj2TVYSMjdVXnDmNi_XA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMzI7aD00NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d07cbeb121c68ed5e1d34236cca98ce5","width":1066,"height":220}},"lazy":false},{"type":"text","content":"BOSTON, December 11, 2025--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-priority gram-negative pathogens.","length":550,"tagName":"p"},{"type":"text","content":"This collaboration marks a historic first in antibiotic research and development: bringing the patient and target product profile (TPP) to the forefront of AI-driven discovery while ensuring an industrial partner is committed to advancing a viable candidate through clinical development.","length":287,"tagName":"p"},{"type":"text","content":"Under the partnership, Phare Bio will deploy its generative AI platform – uniquely parameterized with drug-like properties – to design molecules that meet a pre-defined TPP. Following identification of molecules matching this profile, Basilea will assume responsibility for subsequent development and Phare Bio will be eligible to receive pre-defined success-based payments. The partnership represents a new model for antibiotic innovation, bridging technological advances in drug discovery with industrial expertise and economic sustainability.","length":545,"tagName":"p"},{"type":"text","content":""This partnership is a watershed moment for the field of antimicrobial ...